Frontiers in antibiotics最新文献

{"title":"ENHANCE: a global collaborative research programme investigating the role of homeopathy in antimicrobial stewardship.","authors":"Esther van der Werf","doi":"10.3389/frabi.2026.1892945","DOIUrl":"https://doi.org/10.3389/frabi.2026.1892945","url":null,"abstract":"<p><p>Antimicrobial resistance (AMR) is a leading global health threat. Primary care accounts for approximately 80% of human antibiotic use, making novel non-antibiotic strategies for common self-limiting infections an urgent need. Traditional, Complementary and Integrative Medicine (TCIM), including homeopathy, is widely used worldwide; the existing literature on homeopathy suggests a directional signal of potential reductions in antibiotic use in both human and veterinary settings, though the evidence base remains heterogeneous and methodologically limited. The ENHANCE (rEsearch programme oN Homeopathy and Antimicrobial resistaNCE) international collaborative Programme was established in 2023 to systematically evaluate homeopathy's role in antimicrobial stewardship (AMS) through five integrated workstreams: 1) population studies, 2) AMR literature monitoring, 3) Condition-specific systematic reviews, 4) Core outcome set development, and 5) Primary evidence generation. Completed outputs include systematic reviews for otitis media (2024) and tonsillitis (2026), the first internationally agreed Core Outcome Set for acute otitis media (COS-AOM, 2025), and a nationally representative UK survey showing that homeopathic product use occurs in about 5% of the population (an estimated 2.7 million people), with 4% (around 2.2 million people) consulting homeopathic practitioners (2026). Ongoing work includes systematic reviews and core outcome sets for tonsillitis and sinusitis, and the design of pragmatic primary care trials and real-world evidence studies aligned with WHO- and One Health AMR and AMS strategies. ENHANCE provides the methodologically rigorous, internationally coordinated infrastructure needed to determine whether homeopathy can meaningfully contribute to antibiotic-sparing stewardship.</p>","PeriodicalId":73065,"journal":{"name":"Frontiers in antibiotics","volume":"5 ","pages":"1892945"},"PeriodicalIF":3.9,"publicationDate":"2026-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13471808/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148765412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drivers influencing antibiotics use in pediatric wards across five public hospitals in Zanzibar: a WHO multiple point prevalence survey.","authors":"Faiza Mohamed Juma, Abrahaman Said Msellem, Stanley Mwita, Muhiddin Omar, Khadija Omar, Daniel Joshua, Ahlam Amour, Hafidh Hassan, Salma Hashoul, Muhiddin A Mahmoud, Simon Kühnert, Mayassa Salum Ally, Ali Said, Jyoti Joshi, Fabian Maza, Brecht Ingelbeen, Eveline Thobias Konje, Anja Poulsen, Stine Lund, Jeremiah Seni","doi":"10.3389/frabi.2026.1874316","DOIUrl":"https://doi.org/10.3389/frabi.2026.1874316","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Strengthening antimicrobial stewardship (AMS) programs is a major public health strategy to reduce inappropriate antibiotic use (AMU) and averting antibiotic resistance (AMR). Evidence on AMU and AMS program implementation is widely documented in Tanzania mainland, consistent with previous studies done and other low-and middle-income countries. However, there is limited information on AMU and AMS programs to guide the implementation of the Zanzibar Action Plan on AMR. The objective of this study was to determine the prevalence of AMU, identify factors associated with AMU, and to assess the performance of AMS programs in pediatric wards across hospitals in Zanzibar.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;This repeated cross-sectional study employed the World Health Organization Point Prevalence Survey (WHO-PPS) tool at two time points (February to April 2024 and December 2024 to May 2025), complemented by a one-time WHO-Health Care Facility Core Element Indicators Tool conducted in April 2024 to assess AMS performance. The WHO-PPS study population was children ≤13 years admitted to pediatric wards in five public hospitals in Zanzibar. Healthcare providers and AMS team members reported on Core Element Indicators. The WHO-PPS data were analyzed using descriptive statistics and multivariate modified Poisson regression, while AMS performance was computed as percentage scores per hospital.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Of 943 paediatric patients, 826 (87.6%) received at least one antibiotic. Gentamicin, ampicillin, and ceftriaxone were the most commonly prescribed antibiotics. Watch-category antibiotics accounted for the majority of prescriptions (53.8%), followed by Access (45.8%) and Reserve (0.4%). Community-acquired infections were the predominant indication for antibiotic use, 60.4%, with pneumonia and sepsis being the most common diagnoses. Bacteriological culture testing was performed in only 10.9% of patients, while adherence to national treatment guidelines was 77.8%. Significant predictors of AMU included hospital tier (regional: aPR 1.39, 95%CI 1.30-1.50; and district level: aPR 1.35, 95%CI 1.26-1.46); and higher disease severity shown by ultimately fatal McCabe score, aPR 1.20, 95%CI: 1.07-1.33). The AMS program performance was below the 50% functionality threshold, with low scores observed in leadership, accountability, monitoring and surveillance, and reporting and feedback, alongside limited progress in the establishment of DTC/IPC/AMC committees and implementation of AMS actions.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;Antibiotic use among admitted children was markedly prevalent, notably by the Watch category of antibiotics, and limited reliance on bacteriological culture and suboptimal AMS program performance across hospitals in Zanzibar. These findings highlight important opportunities to strengthen AMS programs and diagnostic practices. Future research should evaluate the appropriateness of antibiotic prescrib","PeriodicalId":73065,"journal":{"name":"Frontiers in antibiotics","volume":"5 ","pages":"1874316"},"PeriodicalIF":3.9,"publicationDate":"2026-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13470639/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148762966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Carbapenem resistance genes and biofilm-virulence uncoupling in <i>Acinetobacter baumannii</i>.","authors":"Shyam Tripathi, Kusum Rani, Rivan Berlia, Amit Sharma, Anandu Hari, Pratibha Gaur, Poornima Sheba Samuel Raj, V Samuel Raj","doi":"10.3389/frabi.2026.1888133","DOIUrl":"10.3389/frabi.2026.1888133","url":null,"abstract":"<p><strong>Introduction: </strong><i>Acinetobacter baumannii</i>, a World Health Organization (WHO) critical-priority pathogen, causes difficult-to-treat nosocomial infections. The link between resistance genes, biofilm, and virulence carriage remains poorly understood in clinical isolates of high-burden South Asian settings. This study intended to thoroughly describe and explain linkages among clinical isolates collected in Haryana, India.</p><p><strong>Methods: </strong>A total of 200 non-duplicate <i>A. baumannii</i> isolates underwent antimicrobial susceptibility testing by broth microdilution against 17 antibiotics, interpreted according to CLSI M100 guidelines (32nd edition). Biofilm forming capacity was quantified using the standardized microtiter plate crystal violet assay. Polymerase chain reaction (PCR) was used to detect six carbapenemase genes (blaOXA-23, blaOXA-24, blaOXA-58, blaNDM-1, blaVIM, and blaIMP), beta-lactamase genes (blaPER-1, AmpC, and blaTEM), and virulence genes (bap, ompA, and csuE). Concordance was assessed by Cohen's κ; gene-resistance and gene-biofilm links were tested using regression and non-parametric analyses. A total of 200 pure, non-duplicate <i>A. baumannii</i> isolates were included and contaminated cultures were excluded. Sample size adequacy was assessed using Buderer's formula based on expected sensitivity, specificity, carbapenem-resistance prevalence, 95% confidence level, and desired precision.</p><p><strong>Results: </strong>Among 200 isolates, 54% were MDR, 34% XDR, and 61% carbapenem-resistant. The blaOXA-23 gene, present in 61%, showed near-perfect concordance with carbapenem resistance (κ = 0.81). Composite carbapenemase carriage improved concordance (κ = 0.88). Biofilm capacity was unrelated to overall resistance, but strong biofilm formers had higher colistin MICs (p = 0.001). Virulence genes (<i>bap</i>, <i>ompA</i>, and <i>csuE</i>) were linked to strong biofilm formation (p < 0.001) without resistance escalation.</p><p><strong>Conclusions: </strong>blaOXA-23 emerged as the dominant genetic driver of carbapenem resistance, underscoring its value in rapid diagnostics. Colistin tolerance was linked to biofilm-associated phenotypes rather than cumulative resistance.</p>","PeriodicalId":73065,"journal":{"name":"Frontiers in antibiotics","volume":"5 ","pages":"1888133"},"PeriodicalIF":3.9,"publicationDate":"2026-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13462743/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148721951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The PATHFAST TB LAM Ag assay: a validated protocol for quantitative tuberculosis treatment monitoring.","authors":"Yassir Adam Shuaib, Stéphane Coisne","doi":"10.3389/frabi.2026.1844052","DOIUrl":"10.3389/frabi.2026.1844052","url":null,"abstract":"<p><p>Tuberculosis (TB) is a global health challenge and is curable, but tools for rapid treatment monitoring are limited. Current methods, like smear microscopy, lack sensitivity, while culture-based approaches require weeks for results and specialized biosafety facilities. This paper presents a comprehensive protocol for the PATHFAST TB LAM Ag assay, a rapid chemiluminescent enzyme immunoassay that quantifies lipoarabinomannan (LAM) mainly in sputum and likely other biological samples within one hour. This protocol details sample collection, heat inactivation for biosafety, and the automated measurement process. Heat inactivation at 100 °C for 20 minutes renders samples non-infectious while preserving LAM for detection. The assay demonstrates excellent analytical performance with a detection limit of 6.67 pg/mL and a linear measurement range of 10.0-50,000 pg/mL. Published clinical evaluation demonstrated 88.8% (95% CI: 80.0-94.0%) sensitivity and 100% (95% CI: 83.9-100%) specificity compared to culture, with strong correlation to bacterial load. The PATHFAST TB LAM Ag assay successfully tracks bacterial decline during treatment, with LAM concentration reductions mirroring culture results but available significantly faster. Unlike culture methods that suffer from contamination (4.2-9.6% invalid results), the PATHFAST TB LAM Ag assay consistently provides valid results. This protocol enables implementation of a rapid, quantitative TB treatment monitoring tool that enhances biosafety, reduces turnaround time, and maintains performance comparable to conventional methods, addressing critical needs in both clinical care and drug development settings.</p>","PeriodicalId":73065,"journal":{"name":"Frontiers in antibiotics","volume":"5 ","pages":"1844052"},"PeriodicalIF":3.9,"publicationDate":"2026-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13457190/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148714839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Fourier transform infrared spectroscopy as a first-line surveillance typing tool for <i>Serratia</i> spp. isolates derived from clinical materials.","authors":"Tristan Lüdecke, Klaus-Peter Hunfeld","doi":"10.3389/frabi.2026.1781370","DOIUrl":"10.3389/frabi.2026.1781370","url":null,"abstract":"<p><strong>Introduction: </strong>Fourier transform infrared spectroscopy (FTIR) has been evaluated as a typing method for a number of pathogens; however, very little research has been conducted on the genus Serratia.</p><p><strong>Methods: </strong>We examined whether FTIR was able to correctly cluster clinical isolates of Serratia to a comparable degree as whole genome sequencing (WGS) coupled with a subsequent bioinformatic comparison, the gold standard for determining phylogenetic relationships in epidemiology. FTIR was performed with the IR Biotyper (Bruker, Bremen, Germany) using the standard settings. Over a period of six weeks, 28 Serratia isolates found in clinical and environmental hygiene samples investigated in our laboratory were collected and preserved. Retrospective strain typing was performed using both methods, and the results were subsequently compared.</p><p><strong>Results: </strong>Our study showed a PPV of 0.842 for the correct identification of closely related isolates and an NPV of 1.0 for the correct identification of unrelated isolates. Concordance was measured using the Adjusted Rand index (AR) and the Adjusted Wallace coefficient (AW), with WGS and subsequent bioinformatic analysis as the reference method. This resulted in an AR of 0.742.</p><p><strong>Discussion: </strong>Our findings indicate, although with some limitations, the utility of using the IR Biotyper as a rapid and cost-effective first-line screening tool for investigating the epidemiological relatedness of Serratia spp. in a clinical microbiology laboratory when an outbreak is suspected. Consequently, the FTIR method may provide a complementary analytical addition to the arsenals of clinical microbiology laboratories that carry out epidemiological surveillance to aid infection control in clinical settings.</p>","PeriodicalId":73065,"journal":{"name":"Frontiers in antibiotics","volume":"5 ","pages":"1781370"},"PeriodicalIF":3.9,"publicationDate":"2026-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13442522/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148686857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Statistical optimization of glucose, sodium citrate and potassium chloride supplementation for enhanced bacteriocin production by <i>Lactococcus lactis</i> MT186647 and <i>Lactobacillus fermentum</i> MT186598 isolated from fermenting <i>Pentaclethra macrophylla</i> benth.","authors":"Chijioke Ethel Onwuakor, Anayochukwu Chibuike Ngene","doi":"10.3389/frabi.2026.1907088","DOIUrl":"10.3389/frabi.2026.1907088","url":null,"abstract":"<p><p>Bacteriocin production by lactic acid bacteria (LAB) is strongly conditioned by growth-medium composition, and adjusting ingredients offers a low-cost route to enhanced yield. Response surface methodology (RSM) based on a three-factor, five-level central composite design (CCD) was used to optimize supplementation of an African oil bean seed (<i>Pentaclethra macrophylla</i> Benth) extract broth with glucose, sodium citrate and potassium chloride for two LAB isolated from the seed and identified by 16S rRNA sequencing, <i>Lactococcus lactis</i> MT186647 and <i>Lactobacillus fermentum</i> MT186598. Twenty runs per organism were performed; bacteriocin activity was determined by the zone of inhibition against <i>Staphylococcus aureus</i> ATCC 19095 by agar well diffusion. For both isolates, glucose exerted a significant negative linear effect and all three supplements significant negative quadratic effects, while no two-factor interaction reached significance, indicating an additive response. The second-order models accounted for 71.85% (<i>L. lactis</i>; p = 0.060) and 73.15% (<i>L. fermentum</i>; p = 0.050) of the variation, with significant lack-of-fit; the regression was therefore only marginally significant, and the predicted R² was 0.00%, indicating no demonstrated ability to predict new runs. The desirability-based optima (6.35/0.55/1.78 g/L glucose/sodium citrate/potassium chloride for <i>L. lactis</i>; 6.44/0.55/1.59 g/L for <i>L. fermentum</i>; predicted zones 13.12 and 12.74 mm) are best interpreted as an estimated optimal region rather than a quantitatively predictive optimum. Validation under these optima combined with the previously established optimal culture conditions (1.9% NaCl, 31 °C, initial pH 6.0) produced zones of 15.22 mm (<i>L. lactis</i>) and 14.96 mm (<i>L. fermentum</i>), exceeding the supplementation-only model estimates by 16.0% and 17.4% and the previously reported culture-condition-only outcomes (13.33 and 11.75 mm) by 14.2% and 27.3%. Because these differences were not tested statistically and partly reflect the fixed 1.9% NaCl (optimized separately and absent from the supplement CCD), the two optimization layers are interpreted as combining additively rather than demonstrating an established synergy. Moderate, balanced supplementation with inexpensive, food-grade additives can substantially enhance bacteriocin yield, supporting further development, subject to confirmatory multi-point validation, of <i>L. lactis</i> MT186647 and <i>L. fermentum</i> MT186598 as starter or protective cultures for the controlled fermentation of <i>P. macrophylla</i> to <i>Ugba</i>.</p>","PeriodicalId":73065,"journal":{"name":"Frontiers in antibiotics","volume":"5 ","pages":"1907088"},"PeriodicalIF":3.9,"publicationDate":"2026-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13445716/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148686920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Linezolid MIC creep among clinically significant <i>S. aureus</i>: a retrospective eight-year study.","authors":"Chinchana Shylaja Eshwarappa, Veerabhadra Swamy Gs, Supreetha R Shettar, Yogeesh D Maheshwarappa, Mahadevaiah Neelambike Sumana, Tejashree A, Rashmi P Mahale, Sowmya Gs, Morubagal Raghavendra Rao, Ranjitha Shankaregowda, Vidyavathi B Chitaragi, Deepashree R, Sujatha Sr, Neetha S Murthy, Badveti Satya Sai, Vasimalli Vinay Kumar","doi":"10.3389/frabi.2026.1814348","DOIUrl":"10.3389/frabi.2026.1814348","url":null,"abstract":"<p><strong>Introduction: </strong>The rising threat of antimicrobial resistance, particularly the phenomenon of MIC creep, poses a significant challenge to the clinical effectiveness of key antibiotics. Linezolid is a crucial last-resort agent for treating severe infections caused by Gram-positive pathogens, including methicillin-resistant <i>Staphylococcus aureus</i> (MRSA). This study aimed to evaluate the temporal trends of linezolid minimum inhibitory concentrations (MICs) in clinical <i>S. aureus</i> isolates at a tertiary care hospital over an eight-year period.</p><p><strong>Methods: </strong>A retrospective study was conducted on clinical <i>S. aureus</i> isolates over eight years from 2017-2024 in a tertiary care hospital. MICs were determined using the VITEK-2 system and interpreted according to CLSI guidelines. Data were analyzed using IBM SPSS Statistics version 20.0.</p><p><strong>Results: </strong>From 2017 to 2024, A total of 4,325 <i>S. aureus</i> isolates were analyzed, comprising 2,682 (62.01%) MSSA and 1,643 (37.98%) MRSA. The mean linezolid MIC for MSSA increased from 1.41 ± 0.53 µg/mL (2017) to 1.72 ± 0.45 µg/mL (2024), and for MRSA from 1.34 ± 0.47 µg/mL (2017) to 1.78 ± 0.42 µg/mL (2024). A progressive rightward shift in MIC distribution from 1 µg/mL to 2 µg/mL was observed in both groups. Spearman's rank correlation demonstrated a significant positive trend (MSSA: <i>r_s</i>  = 0.893, <i>p</i> = 0.001; MRSA: <i>r_s</i>  = 0.857, <i>p</i> = 0.001), consistent with the \"MIC creep.\" All isolates remained within the CLSI susceptibility breakpoint (≤ 4 µg/mL), and no high-level resistance was detected.</p><p><strong>Conclusion: </strong>Linezolid continues to be highly effective; however, the progressive MIC creep from 1 µg/mL to 2 µg/mL indicates emerging reduced susceptibility. These findings stress the need for ongoing MIC surveillance and strict antibiotic stewardship to preserve linezolid efficacy.</p>","PeriodicalId":73065,"journal":{"name":"Frontiers in antibiotics","volume":"5 ","pages":"1814348"},"PeriodicalIF":3.9,"publicationDate":"2026-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13418403/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148622050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial: Accelerating antibiotic development from natural products: tackling antimicrobial resistance (AMR).","authors":"Sanjib Bhakta, Cynthia Amaning Danquah, RuAngelie Edrada-Ebel, Simon Gibbons","doi":"10.3389/frabi.2026.1898318","DOIUrl":"10.3389/frabi.2026.1898318","url":null,"abstract":"<p><p>Accelerating antibiotic development from natural products. Natural products with antimicrobial activity can act through multiple mechanisms to overcome antibiotic resistance. These include directly inhibiting bacterial growth, reversing resistance by blocking efflux pumps and disrupting biofilms, and strengthening host defenses. Together, these strategies help restore antibiotic effectiveness, overcome resistance, and support more sustainable approaches to treating infections. Image created by Dr Ankita Nag in BioRender. (https://BioRender.com/6c0p6qp), licensed under CC BY 4.0.Infographic illustrating key natural sources of antimicrobial compounds, such as plants, microbes, fungi, endophytes, and marine life, alongside antimicrobial strategies including inhibiting bacterial survival, enhancing host defense, and reversing resistance, with a diagram detailing bacterial drug resistance mechanisms like drug modification, target polymorphism, impermeability, and efflux.</p>","PeriodicalId":73065,"journal":{"name":"Frontiers in antibiotics","volume":"5 ","pages":"1898318"},"PeriodicalIF":3.9,"publicationDate":"2026-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13358889/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148439047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial: Natural products and microbial interactions: from antimicrobial activity to microbial modulation.","authors":"Pablo Mendez-Pfeiffer, Manuel G Ballesteros-Monrreal, Mayra Mendez-Encinas, Bryan Ortiz, Yaxsier De Armas","doi":"10.3389/frabi.2026.1901611","DOIUrl":"10.3389/frabi.2026.1901611","url":null,"abstract":"","PeriodicalId":73065,"journal":{"name":"Frontiers in antibiotics","volume":"5 ","pages":"1901611"},"PeriodicalIF":3.9,"publicationDate":"2026-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13333725/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148439053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coagulation dysfunction events associated with novel tetracycline-class drugs: a disproportionality and Bayesian analysis based on the FAERS database.","authors":"Hongxin Li, Jun Wang, Lingjun Kong, Qingwang Wei, Chengwu Shen, Dongna Zou","doi":"10.3389/frabi.2026.1781902","DOIUrl":"10.3389/frabi.2026.1781902","url":null,"abstract":"<p><strong>Introduction: </strong>In contemporary clinical practice, novel tetracycline-class antimicrobial agents have been increasingly utilized due to their favorable pharmacological profiles. However, the potential association between novel tetracycline-class drugs and coagulation dysfunction is relatively underreported in the literature. This study utilizes the FDA Adverse Event Reporting System (FAERS) to identify and analyze risk signals for coagulation disorders associated with three commonly used the novel tetracyclines in clinical practice. The findings are expected to provide valuable references for clinicians in the targeted monitoring of adverse drug reactions.</p><p><strong>Methods: </strong>Coagulation dysfunction reports associated with the novel tetracycline-class drugs, submitted to the FDA Adverse Event Reporting System (FAERS) from January 2004 to December 2024, were collected. Data mining was performed using the ROR, PRR, BCPNN, and MGPS. All data extraction was conducted using R software (version 4.4.2).It should be noted that FAERS is a spontaneous reporting system without exposure denominators and is subject to reporting bias and confounding factors.</p><p><strong>Results: </strong>A total of 346 coagulation dysfunction reports with the novel tetracycline-class drugs as suspected drugs were screened, including 327 for tigecycline, 6 for omadacycline, and 13 for eravacycline. Disproportionate reporting signals of coagulation dysfunction were detected for both tigecycline and eravacycline, with tigecycline showing the strongest signal [ROR = 46.85 (42.29-51.91)]. Subgroup analyses by age, gender, and dosage revealed a higher proportion of male patients receiving tigecycline and eravacycline. while tigecycline and eravacycline exhibited a stronger disproportionate reporting signal in male patients over 65 years old. Omadacycline showed stronger disproportionate reporting signal at a daily dose of 100 mg. The peak onset time for omadacycline was consistently 9 days. However, all subgroup findings for omadacycline and eravacycline should be interpreted with extreme caution due to the limited number of reports. These observations are considered exploratory rather than confirmatory.</p><p><strong>Conclusion: </strong>Disproportionality analysis identified prominent signals of coagulation dysfunction signals associated with tigecycline and eravacycline. Distinctive reporting patterns of coagulation abnormalities were observed across the three novel tetracyclines, with visible discrepancies in patient age, gender, therapeutic indications, daily dosage, clinical outcomes, and adverse event onset time. Based on the above findings, clinicians should maintain high vigilance against the potential coagulation abnormalities induced by novel tetracyclines, and implement standardized and rational therapeutic drug monitoring during clinical medication practice.</p>","PeriodicalId":73065,"journal":{"name":"Frontiers in antibiotics","volume":"5 ","pages":"1781902"},"PeriodicalIF":3.9,"publicationDate":"2026-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13279702/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148297532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}